Symptoms include: Fatigue and weakness Chronic burning in the throat and nasal passages Coughing, wheezing, and shortness of breath Loss of balance Depression and/or anxiety Skin rashes Eye irritation or tearing of the eyes Headache and/or light sensitivity Hearing loss Heightened sensitivity to chemicals and foods Irregular heartbeat Morning stiffness and/or joint pain Muscle weakness Sleep problems Poor memory, difficulty finding words Slower reaction time Vision changes Difficulty concentrating Abdominal pain, diarrhea, and/or bloating Unusual skin sensations, tingling, and numbness Increased urinary frequency or increased thirst Disorientation and/or dizziness Static shocks or metallic taste in the mouth Additionally, mycotoxin toxicity is linked explicitly to neurological symptoms, with patients reporting cognitive, emotional, and behavioral effects
Removal from Category 2 means the FDA no longer considers BPC-157 to pose the level of safety risk that warrants this restriction
Advances in Experimental Medicine and Biology , 1155, 13-24
Supplies and equipment Beyond basic reconstitution supplies, some protocols require additional equipment
This central system of photosynthetic regulation is based on the redox modulation of Cys residues on proteins such as FBPase that have a high intrinsic reactivity
When delivered intravenously, Glutathione bypasses the body's sluggish and often unsuccessful digestive process
